Background: Tripterine (TRI), an active monomer in Tripterygium wilfordii, has significant
pharmacological activities, such as anti-inflammatory, immunosuppressive and anti-tumor activities.
TRI may be used to treat allergic diseases because of its characteristics of immunosuppression.
Objective: This study aims to explore the anti-allergic effect of TRI.
Methods: It was tested in vivo and in vitro in this study.
Results: The results showed that TRI could significantly inhibit histamine release from rat peritoneal
mast cells; the inhibitory effect of TRI on histamine release was stronger than that of other known histamine
inhibitors such as disodium cromoglyceride. TRI also significantly inhibited systemic anaphylactic
shock induced by compound 48/80 and skin allergy induced by IgE, and inhibited the expression
of inflammatory factors secreted by Human Mast Cells (HMC-1) induced by Phorbol 12-Myristate 13-
Acetate (PMA) and calcium carrier A23187. In the animal model of allergic rhinitis induced by Ovalbumin
(OA), the scores of friction, histamine, IgE, inflammatory factors and inflammatory cells decreased
after TRI was administered orally or nasally.
Conclusion: TRI, as an active immunoregulatory factor, has great potential in the treatment of mast
cell-mediated allergic diseases.